Lymphatic Education
& Research Network

Other Grants & Awards Programs

• Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases:  TACs and RMU

  Title:  Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed) - RFA- AR -21-016

  The purpose of this FOA is to establish Technology and Analytic Cores (TACs) and a Research Management Unit (RMU) for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) Program. The TACs include the Technology Cores and the specialized Tissue Repository and Systems Biology Cores. The goal of the AMP AIM Program is to gain a comprehensive understanding of cellular and molecular disease pathways and to identify novel targets for intervention. TACs will work together to test, optimize and apply state-of-the-art and next-generation high-dimensional, high-resolution technologies to interrogate and analyze human biopsy tissue and biosamples from patients with rheumatoid arthritis, lupus, psoriatic spectrum disease and Sjögren’s syndrome. The RMU will provide centralized management and operational support to the network including clinical monitoring for the entire AMP AIM program. All Cores and the RMU will work collaboratively with the Disease Teams (RFA-AR-21-015) to identify molecular and cellular pathways of disease by probing the structural, functional and molecular complexities of end organ tissue involvement in relevant patient populations.

  Posted Date:  March 31, 2021
  Open Date (Earliest Submission Date):  June 15, 2021
  Letter of Intent Due Date(s):  June 15, 2021
  Expiration Date:  July 16, 2021

  All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

  Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  No late applications will be accepted for this Funding Opportunity Announcement.

  Learn More >
• Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases

  Title:  Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjögren’s Syndrome (UC2 Clinical Trial Optional) - RFA -AR-21-015

  The purpose of this FOA is to establish Disease Teams for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) Program. Disease Teams (DTs) will focus on one of the following diseases: rheumatoid arthritis, lupus, psoriatic spectrum disease, or Sjögren’s syndrome. The goal of the AMP AIM Program is to gain a comprehensive understanding of cellular and molecular disease pathways and to identify novel targets for intervention. Disease Teams will lead the research efforts to define the most significant scientific opportunities that can be addressed with state of the art and next-generation tissue interrogation technologies in the context of disease de- and reconstruction approaches of AMP AIM. DTs will work collaboratively to identify molecular and cellular pathways of disease by probing the structural, functional and molecular complexities of end organ tissue in relevant patient populations with state-of the art and next generation analytics provided by the Technical and Analytic Cores (RFA-AR-21-016). DTs will work to harmonize, integrate and optimize all aspects of the data generation pipeline, from tissue collection to data analysis and interpretation.

  
  Posted Date:  March 31, 2021
  Open Date (Earliest Submission Date):  June 15, 2021
  Letter of Intent Due Date(s):  June 15, 2021
  Expiration Date:  July 16, 2021

  All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

  Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  No late applications will be accepted for this Funding Opportunity Announcement.

  Learn More >
• 2021 AVF-JOBST Research Grant

  The American Venous Forum (AVF) and the American Venous Forum Foundation (AVFF) seek to advance knowledge, excellence, and innovation in venous and lymphatic health through education, research, and public advocacy.  In 1995, the AVF, in collaboration with JOBST, initiated the JOBST Research Grant in Venous and Lymphatic Diseases.  For more than 20 years, the research developed by grant recipients has helped advance the understanding and treatment of venous and lymphatic diseases.
  

  The AVF Foundation is proud to announce that they are now accepting submissions for the 2021 AVF-JOBST Research Grant which will provide a $90,000 grant over two years for original, basic or clinical research in venous or lymphatic disease.  The competition is open to residents and fellows in a vascular training program, as well as physicians who have completed their training within the past five (5) years.  Applicants are AVF members and based within the United States.
  

  Areas of emphasis:

  -The science of compression therapy for chronic venous insufficiency.
  -Treatment for venous ulceration.
  -Pathophysiology of venous ulceration.
  -Diagnosis of lymphatic diseases.
  -The science of management of lymphatic disease.
  -Diagnosis and management of iliac vein compression.
  -Physiopathology of deep venous thrombosis
  

  Deadline:  Monday, October 12 at 5:00pm ET

  Learn More >
• Patient-Centered Outcomes Research Institute

  PCORI funds research into conditions that affect large numbers of people across a range of populations; conditions that place a heavy burden on individuals, families, specific populations, and society; and rare diseases, which are difficult to study. PCORI funds research through organizations and not individuals.
  

  PCORI funds research that offers patients and caregivers the information they need to make important healthcare decisions. Our scientific research portfolio is divided among two programs, which together reflect our National Priorities for Research. Each program leads the development of PCORI Funding Announcements that may be either broad calls for applications or targeted to specific topics. These programs also participate in the selection of awards and oversee the projects as they progress.

  In addition, the Evaluation and Analysis program provides evaluation expertise, while the Engagement program gives patients, caregivers, clinicians, and other healthcare stakeholders opportunities for meaningful involvement in all our activities.

  Learn More >
• DOD’s Congressionally Directed Medical Research Programs (CDMRP) - BCRP Pre-Announcements

  Last year researchers looking at the intersection of lymphedema and breast cancer were encouraged to compete for funding opportunities through the CDMRP’s Breast Cancer Research Program (BCRP). Please see the information below in this regard.

  The Fiscal Year 2019 (FY19) Defense Appropriation Act provides funding for the peer reviewed programs managed by the Department of Defense (DOD) office of Congressionally Directed Medical Research Programs (CDMRP). Recently released pre-announcements may be found at http://cdmrp.army.mil/pubs/press/press to allow investigators time to plan and develop ideas for submission to the anticipated FY19 funding opportunities.
  
  FY19 funding opportunities are anticipated to be released in January 2019 for the following programs:
  
  Breast Cancer Research Program
  Ovarian Cancer Research Program
  
  Descriptions of each of the anticipated funding opportunities, eligibility, key mechanism elements, and funding can be found in the respective Program pre-announcement.  FY19 pre-announcements can be found in the CDMRP home page features at http://cdmrp.army.mil.
  
  Researchers investigating the intersection of lymphedema and breast cancer may be interested in the following grant opportunities recently released.
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Innovator Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312196
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Fellowship Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312197
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Award Level 4 Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312198
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Era of Hope Scholar Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312195
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Distinguished Investigator Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312176

  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Award Levels 1 and 2
  Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312177

  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Award Level 3 Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312178

  Learn More >
• DOD’s Congressionally Directed Medical Research Programs (CDMRP) - PRMRP Grant Opportunities

  Peer Reviewed Medical Research Program (PRMRP) Grant Opportunities. – PRMRP funds medical research for a list of conditions and diseases that have been identified by Congress as disproportionately affecting military personnel. LE&RN will be working over the course of this year to include “lymphatic diseases” to this list.
  
  This year’s PRMRP includes “burn pit exposures” and “vascular malformations.” Any researchers looking at this connection between burn pit exposures and the onset of lymphedema should look at the opportunities below. Researchers who are working on research involving vascular or lymphatic malformations may also find funding through these opportunities. Researchers are also encouraged to apply for funding through the designation of vascular malformations as this may encompass vascular anomalies of only veins, only lymph vessels, both veins and lymph vessels, or both arteries and veins.
  (https://www.hopkinsmedicine.org/interventional-radiology/conditions/malformations/index.html)

  LE&RN is working to include “lymphatic diseases” as eligible for study through the fiscal year (FY) 2020 PRMRP and this will definitely improve the ability of researchers to compete successfully for this funding, but the categories above should be seen as an opportunity for researchers to get their foot in the PRMRP’s door.
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Investigator-Initiated Research Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312036
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Technology/Therapeutic Development Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312037
  

  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Discovery Award
  Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312033
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Clinical Trial Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312034
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Focused Program Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312035

  Learn More >
• 
  Lymphatic researchers needed for NIH Study Sections

  NIH has requested that LE&RN assemble and deliver to NIH a list of lymphatic researchers who are willing to serve on NIH Study Sections. They have identified the following three Study Sections that review lymphatic grant proposals:

  * Hypertension and Microcirculation (HM) Study Section reviews applications dealing with propulsion of lymph, lymphatic tone, and pathogenesis of lymphedema with more focus on functional studies; sometimes reviews applications about the lymphatic system in infection and inflammation depending on the outcome of research, namely whether focused on lymphatics or infection.
  
  
  * Immunity and Host Defense (IHD) and Innate Immunity and Inflammation (III) Study Sections may review applications that address lymphatic role in infection.
  
  
  * Cardiovascular Differentiation and Development (CDD) Study Section reviews applications involving lymphatic development, lymphangiogenesis, and lymphedema focusing on structure.

  If you are willing to serve on one or more of the above-identified NIH Study Sections, please contact LE&RN at LERN@LymphaticNetwork.org with the following information:

  * Name
  * Affiliation
  * Study Section(s) on which you are willing to serve
  * In 50 words or less, your qualifications for each Study Section selected
  * Include CV

  Investigators will not be able to review their own research or research on which they are collaborators. However, this will not prevent your research from being reviewed by the Study Section. Per NIH: If a researcher is on a Study Section and has an application, his or her application is reviewed by a special emphasis panel. This is a common practice that happens all the time. This should not be an obstacle to joining a Study Section.

• Online Partnership to Accelerate Research

  OnPAR (Online Partnership to Accelerate Research) is a matchmaking platform where applicants and non-government funders come together.  Leidos Health’s Life Sciences has partnered with NIH and other funding organizations to accelerate the biomedical research and development enterprise by matching high-scoring unfunded applications with private biomedical foundations and/or industries seeking to fund promising research via OnPAR (e.g., for NIH these would be applications within the 30th percentile but are beyond the funding cutoff).

  OnPAR has member organizations and matches the unfunded applications with the funding organization.  For more information, please visit https://onpar.leidosweb.com/.

  Learn More >